SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
Amendment No. 1
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities and Exchange Act of 1934
Date of Report (Date of earliest event reported) May 20, 2002
INCARA PHARMACEUTICALS CORPORATION
----------------------------------------------
(Exact Name of Registrant as Specified in its Charter)
Delaware
--------------------------------------
(State or other jurisdiction of incorporation)
0-27410 56-1924222
---------------------------------- --------------------------------------
(Commission File Number) (I.R.S. Employer Identification Number)
P.O. Box 14287
79 T.W. Alexander Drive
4401 Research Commons, Suite 200
Research Triangle Park, NC 27709
--------------------------------
(Address of principal executive office) (Zip Code)
Registrant's telephone number, including area code 919-558-8688
---------------------------
Item 7. Financial Statements and Exhibits
------------------------------------------
(a) Exhibits
Exhibit 10.84* Securities Purchase Agreement dated as of May 15, 2002, among
Incara Pharmaceuticals Corporation, Aeolus Pharmaceuticals,
Inc., Elan Pharma International Limited and Elan International
Services, Ltd.
Exhibit 99.1 Unaudited pro forma balance sheets as of March 31, 2002
______________
*Incara Pharmaceuticals has requested confidential treatment with respect to
portions of this exhibit. Such portions have been omitted from this exhibit and
have been filed separately with the United States Securities and Exchange
Commission.
SIGNATURE
---------
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
INCARA PHARMACEUTICALS CORPORATION
Date: May 24, 2002 By: /s/ Richard W. Reichow
----------------------------------------------
Richard W. Reichow, Executive Vice President,
Chief Financial Officer and Treasurer
(Principal Financial and Accounting Officer)
2